The DOI matches its Crossref record; 40 of the 43 references it cites were found in a registry or an index.
A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas
Open accessPublished version of a preprint
Abstract
Purpose: Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated kinase/STAT signaling. This first-in-human phase I clinical trial aimed to determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), and appropriate dose for phase II studies; characterize pharmacokinetic and pharmacodynamic parameters; and assess antitumor activity. Experimental Design: Bardoxolone methyl was administered orally once daily for 21 days of a 28-day cycle. An accelerated titration design was employed until a grade 2–related adverse event occurred. A standard 3 + 3 dose escalation was then employed until the MTD was reached. Single dose and steady-state plasma pharmacokinetics of the drug were characterized. Assessment of Nrf2 activation was examined in peripheral blood mononuclear cells (PBMC) by measuring NAD(P)H:quinone oxidoreductase (NQO1) mRNA levels. Immunohistochemical assessment of markers of inflammation, cell cycle, and apoptosis was carried out on tumor biopsies. Results: The DLTs were grade 3 reversible liver transaminase elevations. The MTD was established as 900 mg/d. A complete tumor response occurred in a mantle cell lymphoma patient, and a partial response was observed in an anaplastic thyroid carcinoma patient. NQO1 mRNA levels increased in PBMCs, and NF-κB and cyclin D1 levels decreased in tumor biopsies. Estimated glomerular filtration rate (eGFR) was also increased. Conclusions: Bardoxolone methyl was well tolerated with an MTD of 900 mg/d. The increase in eGFR suggests that bardoxolone methyl might be beneficial in chronic kidney disease. Objective tumor responses and pharmacodynamic effects were observed, supporting continued development of other synthetic triterpenoids in cancer. Clin Cancer Res; 18(12); 3396–406. ©2012 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In another Phase I trial of CDDO-Me in patients with advanced solid tumors and lymphomas, a complete tumor response occurred in one mantle cell lymphoma patient and a partial response was observed in an anaplastic thyroid carcinoma patient at a dose of 900 mg/day.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Pharmacokinetic parameters suggest that CDDO-Me has a slow and saturable oral absorption, long terminal-phase half-life (39 hours at 900 mg/day), nonlinear dose-dependent exposures at high doses (600–1300 mg/day), and high interpatient variability.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“Pharmacokinetic parameters suggest that CDDO-Me has a slow and saturable oral absorption, long terminal-phase half-life (39 hours at 900 mg/day), nonlinear dose-dependent exposures at high doses (600–1300 mg/day), and high interpatient variability.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the data appeared encouraging enough to support continued development of other synthetic triterpenoids as anticancer agents (Hong et al., 2012).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“Pharmacokinetic parameters suggest that CDDO-Me has a slow and saturable oral absorption, long terminal-phase half-life (39 hours at 900 mg/day), nonlinear dose-dependent exposures at high doses (600–1300 mg/day), and high interpatient variability.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“Pharmacokinetic parameters suggest that CDDO-Me has a slow and saturable oral absorption, long terminal-phase half-life (39 hours at 900 mg/day), nonlinear dose-dependent exposures at high doses (600–1300 mg/day), and high interpatient variability.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“Dose-limiting toxicities were grade 3 liver transaminase elevations that were reversible.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“In clinical trials, CDDO-Me showed therapeutic activities against several types of cancers.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Hong et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cheson, B. D., Horning, S., Coiffier, B., Shipp, M., Fisher, R. I., Connors, J. M., Lister, T., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,210
Bioanalytical Method Validation—A Revisit with a Decade of Progress
Shah, V. P., Midha, K. K., Findlay, J. W. A., Hill, H. M., Hulse, J. D., McGilveray, I. J., McKay, G., Miller, K. J., Patnaik, R. N., Powell, M. L., et al. (2000) · Pharmaceutical Research · doi:10.1023/a:1007669411738 · Cited by 1,574
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Self-citationMalhotra, D., Portales-Casamar, É., Singh, A., Srivastava, S., Arenillas, D. J., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq212 · Cited by 812
Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis
Li, W., Khor, T. O., Xu, C., Shen, G., Jeong, W.-S., Yu, S., & Kong, A.-N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.017 · Cited by 738
Dinkova‐Kostova, A. T., Liby, K. T., Stephenson, K. K., Holtzclaw, W. D., Gao, X., Suh, N., Williams, C. R., Risingsong, R., Honda, T., Gribble, G. W., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500815102 · Cited by 575
Pueyo, M. E., Gonzalez, W., Nicoletti, A., Savoie, F., Arnal, J., & Michel, J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.3.645 · Cited by 523
Oxidative Stress Is Progressively Enhanced With Advancing Stages of CKD
Dounousi, E. C., Papavasiliou, E. C., Makedou, A., Ioannou, K. I., Katopodis, K. P., Tselepis, A. D., Siamopoulos, K. C., & Tsakiris, D. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.08.015 · Cited by 412
Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide
Thimmulappa, R. K., Scollick, C., Traore, K., Yates, M. S., Trush, M. A., Liby, K. T., Sporn, M. B., Yamamoto, M. P., Kensler, T. W., & Biswal, S. S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.102 · Cited by 360
Cited by
Sorted by citations
Items 101–200 of 245
Should We Increase GFR with Bardoxolone in Alport Syndrome?
Baigent, C., & Lennon, R. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017101062 · Cited by 39
Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives
Li, J., Cai, Z., Li, X., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01223 · Cited by 39
Similie, D., Minda, D. I., Bora, L., Kroškins, V., Lugiņina, J., Turks, M., Dehelean, C. A., & Danciu, C. (2024) · Antioxidants · doi:10.3390/antiox13080952 · Cited by 37
Amatruda, M., Gembillo, G., Giuffrida, A. E., Santoro, D., & Conti, G. (2021) · Medicina · doi:10.3390/medicina57090868 · Cited by 38
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Bais, T., Gansevoort, R. T., & Meijer, E. (2022) · Drugs · doi:10.1007/s40265-022-01745-9 · Cited by 38
Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury
Mapuskar, K. A., Pulliam, C. F., Zepeda‐Orozco, D., Griffin, B. R., Furqan, M., Spitz, D. R., & Allen, B. G. (2023) · Antioxidants · doi:10.3390/antiox12091728 · Cited by 37
Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by transcription factor Nrf2
Miura, T., Taketomi, A., Nishinaka, T., & Terada, T. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.11.023 · Cited by 37
Lee, J., Pandey, A. K., Venkatesh, S., Thilagavathi, J., Honda, T., Singh, K. D., & Suzuki, C. K. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101719 · Cited by 33
Camer, D., Yu, Y., Szabo, A., Dinh, C. H. L., Wang, H., Cheng, L., & Huang, X. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.018 · Cited by 34
Lange, M., Abhari, B. A., Hinrichs, T. M., Fulda, S., & Liese, J. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.08.011 · Cited by 34
CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
Ball, M. S., Shipman, E. P., Kim, H. J., Liby, K. T., & Pioli, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149600 · Cited by 34
Huang, S., Gong, S., Zhao, Y., Ye, M., Li, J., He, Q., Qiao, H., Tan, X.-R., Wang, J.-Y., Liang, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49675-2 · Cited by 37
The Dual Role of NRF2 in Colorectal Cancer: Targeting NRF2 as a Potential Therapeutic Approach
Hu, M., Yuan, L., & Zhu, J. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s479794 · Cited by 32
Harnessing myeloid cells in cancer
Park, S., Pylaeva, E., Bhuria, V., Gambardella, A. R., Schiavoni, G., Mougiakakos, D., Kim, S.-H., & Jabłońska, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02249-2 · Cited by 35
Ai, Y., Hu, Y., Kang, F., Lai, Y., Jia, Y., Huang, Z., Peng, S., Ji, H., Tian, J., & Zhang, Y. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5020023 · Cited by 32
Fitzpatrick, L. R., Stonesifer, E., Small, J. S., & Liby, K. T. (2014) · Inflammopharmacology · doi:10.1007/s10787-014-0203-2 · Cited by 32
Shen, J., Rasmussen, M., Dong, Q., Tepel, M., & Scholze, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9091879 · Cited by 32
Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
Qin, D., Tang, C., Yang, L. C., Lei, H., Wei, W., Wang, Y., Ma, C., Gao, F., Xu, H., & Wu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132337 · Cited by 29
Albini, A., Bassani, B., Baci, D., Dallaglio, K., Gallazzi, M., Corradino, P., Bruno, A., & Noonan, D. M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170920144130 · Cited by 29
CDDO and Its Role in Chronic Diseases
Mathis, B. J., & Cui, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41342-6_13 · Cited by 28
Kasiappan, R., Jutooru, I., Mohankumar, K., Karki, K., Lacey, A., & Safe, S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1071 · Cited by 24
Lupeol induces immunity and protective efficacy in a murine model against visceral leishmaniasis
Kaur, G., Chauhan, K., & Kaur, S. (2019) · Parasitology · doi:10.1017/s0031182019000659 · Cited by 29
Dinh, C. H. L., Szabo, A., Camer, D., Yu, Y., Wang, H., & Huang, X. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.01.025 · Cited by 27
Transcription Factors as Therapeutic Targets in Chronic Kidney Disease
Hishikawa, A., Hayashi, K., & Itoh, H. (2018) · Molecules · doi:10.3390/molecules23051123 · Cited by 26
The Search for Anticancer Agents from Tropical Plants
Henkin, J. M., Ren, Y., Soejarto, D. D., & Kinghorn, A. D. (2018) · Fortschritte der Chemie Organischer Naturstoffe/Fortschritte der Chemie organischer Naturstoffe/Progress in the chemistry of organic natural products · doi:10.1007/978-3-319-93506-5_1 · Cited by 27
Abdo, S. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000547 · Cited by 25
Cuadrado, A., Cazalla, E., Bach, A., Bathish, B., Naidu, S. D., DeNicola, G. M., Dinkova-Kostova, A. T., Fernández-Ginés, R., Grochot-Przeczek, A., Hayes, J. D., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103569 · Cited by 28
Mondal, D., Narwani, D., Notta, S., Ghaffar, D., Mardhekar, N. M., & Quadri, S. S. A. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.71 · Cited by 25
Have we reached the limits for the treatment of diabetic nephropathy?
Hajhosseiny, R., Khavandi, K., Jivraj, N. K., Mashayekhi, S., Goldsmith, D. J. A., & Malik, R. A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.892580 · Cited by 25
Chemical Tuning Enhances Both Potency Toward Nrf2 and In Vitro Therapeutic Index of Triterpenoids
Copple, I. M., Shelton, L. M., Walsh, J., Kratschmar, D. V., Lister, A., Odermatt, A., Goldring, C. E., Dinkova‐Kostova, A. T., Honda, T., & Park, B. K. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu080 · Cited by 26
Bardoxolone Methyl Prevents High-Fat Diet-Induced Colon Inflammation in Mice
Dinh, C. H. L., Yu, Y., Szabo, A., Zhang, Q., Zhang, P., & Huang, X. (2016) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155416631803 · Cited by 25
Khurana, N., Chandra, P. K., Kim, H., Abdel‐Mageed, A. B., Mondal, D., & Sikka, S. C. (2020) · Antioxidants · doi:10.3390/antiox9010068 · Cited by 24
Chen, J., Zhang, W., Chen, P., Fan, J., Zhong, X., & Tang, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119185 · Cited by 24
Jeong, S. A., Kim, I. Y., Lee, A. R., Yoon, M. J., Cho, H., Lee, J., & Choi, K. S. (2015) · Oncotarget · doi:10.18632/oncotarget.4065 · Cited by 24
Crowley, V. M., Ayi, K., Lu, Z., Liby, K. T., Sporn, M. B., & Kain, K. C. (2017) · Malaria Journal · doi:10.1186/s12936-017-2109-0 · Cited by 24
Kangussu-Marcolino, M. M., Ehrenkaufer, G. M., Chen, E., Debnath, A., & Singh, U. (2019) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2019.10.003 · Cited by 23
Recent Progress in Oleanolic Acid: Structural Modification and Biological Activity
Wang, W., Li, Y., Li, Y., Sun, D., Li, H., & Chen, L. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211105101231 · Cited by 23
Raghuvanshi, D. S., Verma, N., Singh, S., Luqman, S., Gupta, A. C., Bawankule, D. U., Tandon, S., Nagar, A., Kumar, Y., & Khan, F. (2018) · New Journal of Chemistry · doi:10.1039/c8nj03564d · Cited by 23
Yukitake, H., Takizawa, M., & Kimura, H. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/8584930 · Cited by 23
The paradox of bardoxolone methyl: a call for every witness on the stand?
Laecke, S. V., Biesen, W. V., & Vanholder, R. C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12356 · Cited by 22
Qin, Y. W., Deng, W., Ekmekçioglu, S., & Grimm, E. A. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12031 · Cited by 22
Altered NRF2 signalling in systemic redox imbalance: Insights from non-communicable diseases
Jakubowska, M. A., Costa, V. M., Krzeptowski, W., Dominkuš, P. P., Santos, M., Demirdöğen, B. C., Genç, Ş., Trougakos, I. P., Kanninen, K. M., Winklhofer‐Roob, B. M., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103891 · Cited by 23
Kolsi, L. E., Leal, A. S., Yli‐Kauhaluoma, J. T., Liby, K. T., & Moreira, V. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-34131-1 · Cited by 21
The Potential of Nrf2 Activation as a Therapeutic Target in Systemic Lupus Erythematosus
Barati, M. T., & Caster, D. J. (2022) · Metabolites · doi:10.3390/metabo12020151 · Cited by 23
Eitas, T. K., Stepp, W. H., Sjeklocha, L. M., Long, C. V., Riley, C., Callahan, J. F., Sánchez, Y., Gough, P. J., Knowlin, L. T., van Duin, D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184164 · Cited by 21
The potential roles of Nrf2/Keap1 signaling in anticancer drug interactions
Wang, J., Jin, Y., Cao, M., Zhao, Z., Cao, B., & Yu, S. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100028 · Cited by 20
CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
El-Ashmawy, M., Delgado, O., Cardentey, A., Wright, W. E., & Shay, J. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115600 · Cited by 19
Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma
Roemeling, C. A. V., & Copland, J. A. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1086341 · Cited by 19
Design, synthesis, and biological activity of second-generation synthetic oleanane triterpenoids
Fu, L., Lin, Q.-X., Onyango, E. O., Liby, K. T., Sporn, M. B., & Gribble, G. W. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01420a · Cited by 19
Nio, Y., Sasai, M., Akahori, Y., Okamura, H., Hasegawa, H., Oshima, M., Watashi, K., Wakita, T., Ryo, A., Tanaka, Y., et al. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.104537 · Cited by 18
Liese, J., Hinrichs, T. M., Lange, M., & Fulda, S. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000750 · Cited by 19
Wang, J., Shi, H., Yang, Y. S., & Gong, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1505794 · Cited by 21
Recent Advances in Targeting Human Mitochondrial AAA+ Proteases to Develop Novel Cancer Therapeutics
Wong, K. S., & Houry, W. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8367-0_8 · Cited by 17
Regulation of Mitochondrial Homeostasis and Nrf2 in Kidney Disease: Timing Is Critical
Zhuang, Y., Hu, L., Wu, Y. F., Yang, C., Li, S., Jing, K., & Liu, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/9275056 · Cited by 16
Role of inflammation in the progression of diabetic kidney disease
Chatterjee, A., Tumarin, J., & Prabhakar, S. S. (2024) · Vessel Plus · doi:10.20517/2574-1209.2024.21 · Cited by 18
Discovery of a molecular glue for EGFR degradation
Wang, H., Wang, R., Wang, R., Li, Y., Wang, Z., Zhou, W., Deng, L., Li, X., Li, Z., Yang, Q., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03241-8 · Cited by 18
Lee, Y.-S., Kwon, R. J., Lee, H. S., Chung, J. H., Kim, Y. S., Jeong, H.-S., Park, S.-J., Lee, S. Y., Kim, T., & Yoon, S. H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics17010022 · Cited by 16
Cheng, Z., Li, Y., Zhu, X., Wang, K., Ali, Y., Shu, W., Zhang, T., Zhu, L., Murray, M. T., & Zhou, F. (2021) · Planta Medica · doi:10.1055/a-1377-2596 · Cited by 17
Kari, E., Teppo, H.-R., Haapasaari, K.-M., Kuusisto, M. E. L., Lemma, A., Karihtala, P., Pirinen, R., Soini, Y., Jantunen, E., Turpeenniemi-Hujanen, T., et al. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205584 · Cited by 16
Cheng, B., Chu, X., Liu, R., Ma, X., Wang, M., Zhang, J., Jiao, P., Gao, Q., Ma, W., Zhang, Y., et al. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00885 · Cited by 15
Bardoxolone-methyl inhibits migration and metabolism in MCF7 cells
Refaat, A., Pararasa, C., Arif, M., Brown, J. E. P., Carmichael, A. R., Ali, S. S., Sakurai, H., & Griffiths, H. R. (2017) · Free Radical Research · doi:10.1080/10715762.2017.1295452 · Cited by 15
Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel Bmi-1-Mediated Antitumor Agents
Yang, L.-F., Xing, Y., Xiao, J.-X., Xie, J., Gao, W., Xie, J., Wang, L., Wang, J., Liu, M., Yi, Z., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00345 · Cited by 15
The role of the Nrf2/Keap1 signaling cascade in mechanobiology and bone health
Priddy, C. N., & Li, J. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101149 · Cited by 15
Daenthanasanmak, A., Bamford, R. N., Yoshioka, M., Yang, S., Homan, P., Karim, B. O., Bryant, B. R., Petrus, M. N., Thomas, C. J., Green, P. L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005948 · Cited by 15
Fu, L., Lin, Q.-X., Liby, K. T., Sporn, M. B., & Gribble, G. W. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00679h · Cited by 15
α-Glucosidase Inhibitors Based on Oleanolic Acid for the Treatment of Immunometabolic Disorders
Petrova, A. V., Babkov, D. A., Khusnutdinova, E. F., Байкова, И. П., Kazakova, O. B., Sokolova, E. V., & Спасов, А. А. (2023) · Applied Sciences · doi:10.3390/app13169269 · Cited by 14
Zhou, Y., Lin, S., Zhong, X., Huang, F., Huang, J., & Xu, L. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02223-9 · Cited by 14
Bardoxolone for CKD: The Paradox of Confusion and Dogma
Avula, U. M. R., Harris, L., & Hassanein, M. (2022) · Kidney360 · doi:10.34067/kid.0000992022 · Cited by 13
Hirano, S., Ichikawa, Y., Sato, B., Takefuji, Y., & Satoh, F. (2023) · Biomedicines · doi:10.3390/biomedicines11102817 · Cited by 12
D’Mello, R. S., Mendon, V., Pai, P., Das, I., & Babitha, K. S. (2025) · 3 Biotech · doi:10.1007/s13205-025-04209-5 · Cited by 12
Synthesis and the antineoplastic activity of imidazolides of betulonic acid
Kazakova, O. B., Medvedeva, N. I., Lopatina, T. V., Николаевна, А. Г., Pugacheva, R. B., Yavorskaya, N. P., Голубева, И. С., & Толстиков, Г. А. (2015) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162015020065 · Cited by 12
Torres-Sanchez, A., Torres, G., Estrada, S., Pérez, D., Garcia, C., Milián, M., Velázquez, E., Molina, V., & Delgado, Y. (2024) · Pharmaceuticals · doi:10.3390/ph17060694 · Cited by 13
Schiavoni, V., Crescenzo, T. D., Membrino, V., Alia, S., Fantone, S., Salvolini, E., & Vignini, A. (2025) · Pharmaceuticals · doi:10.3390/ph18070966 · Cited by 12
Potentially Chemopreventive Triterpenoids and Other Secondary Metabolites From Plants and Fungi
Akihisa, T., Zhang, J., & Tokuda, H. (2016) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63932-5.00001-2 · Cited by 11
First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer
Wang, S., Zhu, H., Li, Y., Ding, J., Wang, F., Ding, L., Wang, X., Zhao, J., Zhang, Y., Yao, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002926 · Cited by 11
Discontinued cardiovascular drugs in 2013 and 2014
Zhao, H.-P., & Xiang, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1051619 · Cited by 11
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells
Jin, U.-H., Cheng, Y., Zhou, B., & Safe, S. H. (2017) · Molecular Pharmacology · doi:10.1124/mol.116.106245 · Cited by 11
Shaharyar, M. A., Banerjee, T., Sengupta, M., Bhowmik, R., Sarkar, A., Mandal, P., Alzarea, S. I., Ghosh, N., Akhtar, J., Kazmi, I. A., et al. (2025) · Planta Medica · doi:10.1055/a-2510-9958 · Cited by 11
Liby, K. T. (2013) · Dose-Response · doi:10.2203/dose-response.13-018.liby · Cited by 10
Jiao, P., Wang, S., Liang, S., Li, M., Gao, Q., Ji, D., Chen, Y., Li, H., Ran, F.-X., Zhang, Y., et al. (2018) · Chinese Chemical Letters · doi:10.1016/j.cclet.2018.10.009 · Cited by 10
Wu, S., Ai, Y., Huang, H., Wu, G., Zhou, S., Hong, W., Akuetteh, P. D. P., Jin, G., Zhao, X., Zhang, Y., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02562-6 · Cited by 9
Teuscher, N. S., Kelley, R. J., Dumas, E. O., Klein, C. E., Awni, W. M., & Meyer, C. J. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.74 · Cited by 9
Self-citationKamel, A. M., Bowlin, S., Anwar, B., Reichard, H. A., Argus, J., & Blair, I. A. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00289 · Cited by 9
Research progress on anti-inflammatory drugs for preventing colitis-associated colorectal cancer
Wang, T. Y., Huang, Y., Jiang, P., Yuan, X., Long, Q., Yan, X., Huang, Y., Wang, Z., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113583 · Cited by 8
Anticancer Effects of Sinocrassulosides VI/VII from Silene viscidula on HeLa Cells
Chen, H., Ma, Q., Xu, W. F., Li, W.-M., Yuan, D., Wu, J., Li, Y., & Jin, F. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/8240820 · Cited by 8
Modulation of Lonp1 Activity by Small Compounds
Zanini, G., Micheloni, G., Sinigaglia, G., Selleri, V., Mattioli, A. V., Nasi, M., Pierri, C. L., & Pinti, M. (2025) · Biomolecules · doi:10.3390/biom15040553 · Cited by 7
Triterpenoid phthalimides as selective anti-cancer agents targeting mitochondrial apoptosis
Kazakova, A., Frydrych, I., Jakubcová, N., Pokorný, J., Lišková, B., Gurská, S., Buriánová, R., Přibylka, A., Džubák, P., Hajdúch, M., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117126 · Cited by 6
Murad, H. Y., Chandra, P. K., Kelly, C. A., Khurana, N., Yu, H., Bortz, E., Hong, S. N., Mondal, D., & Khismatullin, D. B. (2022) · Antioxidants · doi:10.3390/antiox11020341 · Cited by 6
T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages
Torres, G. M., Yang, H.-T., Park, C., Spezza, P. A., Khatwani, N., Bhandari, R., Liby, K. T., & Pioli, P. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.768753 · Cited by 6
Моисеева, Н. И., Eroshenko, D. V., Laletina, L. A., Rybalkina, E. Y., Susova, O. Y., Karamysheva, A. F., Толмачева, И. А., Nazarov, M. A., & Grishko, V. V. (2023) · Biology · doi:10.3390/biology12030415 · Cited by 6
Synthesis of new cyanoethyl derivatives from 3-oxotriterpenoids
Khusnutdinova, E. F., Petrova, A. V., Poptsov, A. I., Lobov, A. N., Smirnova, I. E., & Kukovinets, O. S. (2017) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428017080073 · Cited by 6
Sex-based differences in the NRF2 oxidative stress response: Implications for precision therapeutics
Russomanno, G., Kwiatkowska, K., & Copple, I. M. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104128 · Cited by 5
Ihunnah, C. A., Ghosh, S., Hahn, S. A., Straub, A. C., & Ofori-Acquah, S. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.880834 · Cited by 6
Galiano, V., Encinar, J. A., & Villalaı́n, J. (2020) · The Journal of Membrane Biology · doi:10.1007/s00232-020-00106-5 · Cited by 5
Nrf2 Activation Does Not Protect from Aldosterone-Induced Kidney Damage in Mice
Brinks, R., Wruck, C. J., Schmitz, J., & Schupp, N. (2023) · Antioxidants · doi:10.3390/antiox12030777 · Cited by 5
Wang, Y., Zhou, S., Zhao, R., Hai, P., & Zhe, H. (2016) · PubMed Central · Cited by 5
Zhang, L., Huang, Q., Yang, J., & Hu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-00480-x · Cited by 4
Nagai, K., Fukuno, S., Miura, T., Yasuda-Imanishi, E., & Konishi, H. (2023) · Drug Research · doi:10.1055/a-2111-6649 · Cited by 3
Chang, C.-H., Tsai, H., Kuo, S.-H., Loh, J., Lin, C., Lin, C., & Kwan, A. (2019) · International Surgery · doi:10.9738/intsurg-d-20-00005.1 · Cited by 3
NRF2: A potential target for the treatment of diabetic nephropathy
Zhang, J., Anshul, F., Breidenbach, J. D., Liu, J., & Shaffner, J. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2021-0006 · Cited by 3
Metadata
- Authors
- Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., Mier, J., Konopleva, M., Konoplev, S., Andreeff, M., Kufe, D., Lazarus, H., Shapiro, G. I., & Dezube, B. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Hong, David S.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2012-06-14
- Volume
- 18
- Issue
- 12
- Pages
- 3396-3406
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4494099
- OpenAlex
- W2087928294
- Cited by
- 236
- References
- 43
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 17 · 2023: 14 · 2022: 21 · 2021: 18 · 2020: 17 · 2019: 20 · 2018: 14 · 2017: 18 · 2016: 15 · 2015: 23 · 2014: 17 · 2013: 13 · 2012: 3
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA166480, R01CA042802, P30CA016672)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Physical Sciences › Chemistry › Organic Chemistry › Natural product bioactivities and synthesis
- Keywords
- bardoxolone methyl, synthetic triterpenoids, Nrf2 activation, NF-κB inhibition, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, NQO1, mantle cell lymphoma, anaplastic thyroid carcinoma, advanced solid tumors, anticancer activity, liver transaminase elevation, estimated glomerular filtration rate, chronic kidney disease, oral administration
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Renal Cell, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Kidney Neoplasms, Lymphoma, Male, Melanoma, Middle Aged, Neoplasms, Oleanolic Acid, RNA, Messenger, Thyroid Neoplasms, Colorectal Neoplasms, NF-kappa B, NAD(P)H Dehydrogenase (Quinone), Cyclin D1, Maximum Tolerated Dose, STAT Transcription Factors, NF-E2-Related Factor 2, Janus Kinases, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
